Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1980 3
1982 1
1983 2
1984 1
1985 1
1986 1
1988 3
1990 1
1991 1
1992 2
1993 1
1994 2
1995 3
1996 1
1997 1
1998 1
1999 1
2000 3
2001 1
2002 13
2003 14
2004 8
2005 19
2006 24
2007 26
2008 36
2009 20
2010 23
2011 21
2012 35
2013 42
2014 40
2015 41
2016 52
2017 52
2018 57
2019 71
2020 74
2021 81
2022 81
2023 74
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

839 results

Results by year

Filters applied: . Clear all
Page 1
Breast Cancer Treatment: A Review.
Waks AG, Winer EP. Waks AG, et al. JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323. JAMA. 2019. PMID: 30667505 Review.
Triple-negative breast cancer is more likely to recur than the other 2 subtypes, with 85% 5-year breast cancer-specific survival for stage I triple-negative tumors vs 94% to 99% for hormone receptor positive and ERBB2 positive. Systemic thera …
Triple-negative breast cancer is more likely to recur than the other 2 subtypes, with 85% 5-year breast cancer-specific surviv …
Treatment of breast cancer.
Maughan KL, Lutterbie MA, Ham PS. Maughan KL, et al. Am Fam Physician. 2010 Jun 1;81(11):1339-46. Am Fam Physician. 2010. PMID: 20521754 Free article. Review.
Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. ...In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor- …
Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy. ...In general, …
Update on Pregnancy Following Breast Cancer Diagnosis and Treatment.
Perachino M, Poggio F, Arecco L, Blondeaux E, Spinaci S, Marrocco C, Levaggi A, Lambertini M. Perachino M, et al. Cancer J. 2022 May-Jun 01;28(3):176-182. doi: 10.1097/PPO.0000000000000599. Cancer J. 2022. PMID: 35594464 Review.
Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, conceiving at the end of anticancer treatments should not be discouraged but might be challenging. ...This article reports an updated overview …
Survivorship has become a crucial component in breast cancer care. For women who have not completed their family planning, con …
New treatment options for hormone receptor positive breast cancer in 2023.
Lüftner D. Lüftner D. Curr Opin Obstet Gynecol. 2023 Feb 1;35(1):62-66. doi: 10.1097/GCO.0000000000000834. Epub 2022 Nov 7. Curr Opin Obstet Gynecol. 2023. PMID: 36341983 Review.
PURPOSE OF REVIEW: Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer does respond to chemotherapy but can be addressed with a better therapeutic index by using biologically modified endocrine …
PURPOSE OF REVIEW: Hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) breast …
Treatment of Breast Cancer in Young Adults.
Tesch ME, Partridge AH. Tesch ME, et al. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12. doi: 10.1200/EDBK_360970. Am Soc Clin Oncol Educ Book. 2022. PMID: 35580291 Free article.
Prognostic genomic signatures can spare low-risk young women with hormone receptor-positive breast cancer adjuvant chemotherapy, but management of intermediate-risk patients remains controversial. Ovarian function suppression and extended endocrine …
Prognostic genomic signatures can spare low-risk young women with hormone receptor-positive breast cancer adjuva …
Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Hyder T, Marino CC, Ahmad S, Nasrazadani A, Brufsky AM. Hyder T, et al. Front Endocrinol (Lausanne). 2021 Jul 27;12:713700. doi: 10.3389/fendo.2021.713700. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34385978 Free PMC article. Review.
Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of hormone receptor-positive (HR+) breast cancer. While the addition of AI therapy has improved cancer-related outcomes in the management of HR+ breast ca …
Aromatase inhibitors (AIs) are a key component in the chemoprevention and treatment of hormone receptor-positive (HR+) …
An updated review of epidemiology, risk factors, and management of male breast cancer.
Khan NAJ, Tirona M. Khan NAJ, et al. Med Oncol. 2021 Mar 15;38(4):39. doi: 10.1007/s12032-021-01486-x. Med Oncol. 2021. PMID: 33721121 Review.
Since the majority of MBC are hormone receptor positive (HR+), adjuvant hormonal therapy is required. Tamoxifen for a total of 5 to 10 years is the mainstay adjuvant hormonal therapy. The role of neoadjuvant and adjuvant chemothera …
Since the majority of MBC are hormone receptor positive (HR+), adjuvant hormonal therapy is required. Tam …
Management of Male Breast Cancer: ASCO Guideline.
Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, Plichta JK, Ricker C, Roshal A, Ruddy KJ, Safer JD, Van Poznak C, Yung RL, Giordano SH. Hassett MJ, et al. J Clin Oncol. 2020 Jun 1;38(16):1849-1863. doi: 10.1200/JCO.19.03120. Epub 2020 Feb 14. J Clin Oncol. 2020. PMID: 32058842
RECOMMENDATIONS: Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone receptor-positive breast cancer who are candidates for adjuvant endocrine therapy should be offered tamoxif …
RECOMMENDATIONS: Many of the management approaches used for men with breast cancer are like those used for women. Men with hormone …
Management of bone loss due to endocrine therapy during cancer treatment.
Khan MI. Khan MI. Osteoporos Int. 2023 Apr;34(4):671-680. doi: 10.1007/s00198-023-06672-3. Epub 2023 Jan 19. Osteoporos Int. 2023. PMID: 36656338 Review.
Bone modifying agents BMAs (oral and IV bisphosphonates, denosumab) are used to treat bone loss due to endocrine therapy in patients with hormone receptor positive (HR +) early breast cancer and non-metastatic prostate cancer (NMPC). ...BMAs to …
Bone modifying agents BMAs (oral and IV bisphosphonates, denosumab) are used to treat bone loss due to endocrine therapy in patients …
The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer.
Wöckel A, Albert US, Janni W, Scharl A, Kreienberg R, Stüber T. Wöckel A, et al. Dtsch Arztebl Int. 2018 May 4;115(18):316-323. doi: 10.3238/arztebl.2018.0316. Dtsch Arztebl Int. 2018. PMID: 29807560 Free PMC article.
BACKGROUND: Breast cancer is the most common cancer in women. The German S3 guideline of 2012 has now been updated to take account of advances in the early detection, diagnostic evaluation, treatment, and follow-up care of this disease. ...All patients with hormo …
BACKGROUND: Breast cancer is the most common cancer in women. The German S3 guideline of 2012 has now been updated to take account of …
839 results